

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## BBI LIFE SCIENCES CORPORATION

### BBI 生命科學有限公司

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1035)

#### APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Liu Bin (“**Mr. Liu**”) has been appointed as a non-executive Director, with effect from 18 April 2020.

This announcement is made by the Board of Directors (the “**Directors**”) (the “**Board**”) of BBI Life Sciences Corporation (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

#### APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that the Company has appointed Mr. Liu as a non-executive Director, with effect from 18 April 2020. The biography of Mr. Liu is as follows:

Mr. Liu Bin (劉斌), aged 37, graduated and obtained a Master of Science Degree and a Bachelor's Degree in biological sciences from Hong Kong University of Sciences & Technology in 2008. Mr. Liu has been the chief administrative officer of the Company since 30 October 2019.

Mr. Liu's remuneration as a non-executive Director is HK\$20,000 per month, which is determined by the Board according to the Company's relevant remuneration policies and his appointment as a non-executive Director does not have a fixed term.

As at the date of this announcement, Mr. Liu confirmed that he did not (i) hold any directorships in other public companies whose securities are listed on any securities market in Hong Kong or overseas in the past three years; (ii) have other major appointments or professional qualifications; (iii) have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company (within the meaning ascribed to such terms under the Listing Rules); (iv) have any other information that is required to be disclosed pursuant to Rule 13.51 (2)(h) to (v) of the Listing Rules ; and (V) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong), and there are no other matters in relation to his appointment as a non-executive Director that need to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its warm welcome to Mr. Liu on his new position.

By order of the Board  
**BBI Life Sciences Corporation**  
**Chairman**  
*Wang Qisong*

Hong Kong, 17 April 2020

As at the date of this announcement, the Board comprises Mr. Wang Qisong, Ms. Wang Luojia and Ms. Wang Jin as executive Directors; Mr. Zhou Mi and Mr. Liu Bin as non-executive Directors; and Mr. Xia Lijun, Mr. Ho Kenneth Kai Chung and Mr. Liu Jianjun as independent non-executive Directors.